BiotechTube
aptaTargets

aptaTargets

Barcelona, Spain· Est.
aptatargets.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $1.5M

Overview

aptaTargets is a Spanish biotechnology company specializing in aptamer-based therapeutics for acute inflammatory conditions. Its lead asset, ApTOLL, a TLR4-targeting aptamer for acute ischemic stroke, has completed a positive Phase 1b/2a trial and received EMA PRIME designation. Following a strategic transfer of ApTOLL to Merck in 2024, aptaTargets is positioned to potentially advance its platform into other acute indications like myocardial infarction and multiple sclerosis.

NeurologyCardiologyImmunology

Technology Platform

Therapeutic aptamer discovery and development platform for targeting inflammatory pathways in acute diseases.

Funding History

1
Total raised:$1.5M
Seed$1.5M

Opportunities

The successful Phase 1b/2a data and EMA PRIME designation for ApTOLL validate the platform and create significant partnership value.
The transfer deal with Merck provides capital to expand the aptamer pipeline into other large acute inflammatory markets like myocardial infarction and neuroinflammatory diseases.

Risk Factors

Future value is dependent on the platform's ability to generate new successful candidates, as the lead asset is now externally controlled.
The company faces typical biotech development risks for any new programs and must compete in crowded therapeutic areas like stroke and cardiology.

Competitive Landscape

In neuroprotection for stroke, ApTOLL's unique TLR4 mechanism faces competition from other anti-inflammatory and neuroprotective approaches. As an aptamer therapeutics company, it competes with other oligonucleotide-based therapy developers and biotechs focused on acute inflammation, but its specific focus and clinical validation provide differentiation.

More companies in RNA Therapeutics (non-mRNA) →More companies in Spain →